Webinar: Dyne Therapeutics — FORZETTO: Understanding the Phase 3 Trial of Zeleciment Rostudirsen
by: Parent Project Muscular Dystrophy
Dyne Therapeutics joins PPMD for a community webinar on October 14, 2026 to present the design of ongoing FORZETTO study on z-rostudirsen (also known as DYNE-251) for individuals living with Duchenne amenable to exon 51 skipping.